Terms ending in 2036
Every in-force patent on Abraxis Bioscience, LLC's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,705,070 | Methods of Assessing Suitability of Use of Pharmaceutical Compositions of Albumin and Poorly Water Soluble Drug In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 10,900,951 | Methods of Assessing Suitability of Use of Pharmaceutical Compositions of Albumin and Paclitaxel In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 11,320,416 | Methods of Assessing Suitability of Use of Pharmaceutical Compositions of Albumin and Poorly Water Soluble Drug In force · Medium confidence | Abraxis Bioscience, LLC | In force | Medium confidence | |
| US 12,061,183 | Methods of Assessing Suitability of Use of Pharmaceutical Compositions of Albumin and Poorly Water Soluble Drug In force · Medium confidence | Abraxis Bioscience, LLC | In force | Medium confidence | |
| US 10,527,604 | Methods of Assessing Suitability of Use of Pharmaceutical Compositions of Albumin and Paclitaxel In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 10,973,806 | Methods of Treating Epithelioid Cell Tumors Comprising Administering a Composition Comprising Nanoparticles Comprising an Mtor Inhibitor and an Albumin In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.